Products for Research Use Only

Parogrelil hydrochloride

CAT: 0931-T28296-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0931-T28296-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
CAS Number
878796-94-2
Target
Others
Related Pathways
Others
Bioactivity
Parogrelil is a phosphodiesterase (PDE3/PDE5A) inhibitor potentially for the treatment of intermittent. Parogrelil suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects. Parogrelil improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Smiles
O=C1C(Br)=C(C(OCCCC2=CC=C(C=C2)Cl)=NN1)NCC3=CC=CN=C3.[H]Cl
Molecular Formula
C19H19BrCl2N4O2
Molecular Weight
486.19
Shipping Conditions
Ice Packs
Storage Temperature
-20°C

Chemical Information

NM-702

Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited

CAS Number878796-94-2
PubChem CID9848253
IUPAC Name5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
Molecular FormulaC19H19BrCl2N4O2
Molecular Weight486.2
Topological Polar Surface Area75.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count8
Heavy Atom Count28
Formal Charge0
Complexity576
SMILES
C1=CC(=CN=C1)CNC2=C(C(=O)NN=C2OCCCC3=CC=C(C=C3)Cl)Br.Cl
InChI
InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H
InChIKey
QWGUGDYWUADMGB-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of NM-702
CAS: 878796-94-2
CID: 9848253
Formula: C19H19BrCl2N4O2
MW: 486.2
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight486.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count8
Exact Mass484.00684
Monoisotopic Mass484.00684
Topological Polar Surface Area75.6 Ų
Heavy Atom Count28
Formal Charge0
Complexity576
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes